Bristol Myers Squibb (CELG-RI) Cost of Revenue (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Cost of Revenue for 18 consecutive years, with $3.7 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Cost of Revenue rose 10.5% year-over-year to $3.7 billion; the TTM figure through Jun 2026 stood at $14.7 billion (up 3.56% YoY), while the FY2025 annual figure was $13.9 billion, changed 0.23% from the prior year.
• Cost of Revenue grew to $3.7 billion in Q2 2026 per CELG-RI's latest filing, from $3.4 billion in the prior quarter.
• Across five years, Cost of Revenue topped out at $4.8 billion in Q4 2024 and bottomed at $2.4 billion in Q3 2022.
• Historically, Cost of Revenue has averaged $3.1 billion across 5 years, with a median of $2.9 billion in 2024.
• Annual changes were most pronounced in 2024 — Cost of Revenue soared 75.3% — and 2025, when it fell 14.86%.
• Bristol Myers Squibb's Cost of Revenue stood at $2.6 billion in 2022, then increased by 5.86% to $2.7 billion in 2023, then jumped by 75.3% to $4.8 billion in 2024, then declined by 14.86% to $4.1 billion in 2025, then slipped by 9.06% to $3.7 billion in 2026.
• Business Quant data shows CELG-RI's Cost of Revenue at $3.7 billion in Q2 2026, $3.4 billion in Q1 2026, and $4.1 billion in Q4 2025.